NCT05581589View on ClinicalTrials.gov

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

February 15, 2027

Study Completion Date

April 30, 2027

Conditions
Muscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
Interventions
PROCEDURE

Lymphadenectomy

Undergo pelvic lymph node dissection

PROCEDURE

Radical Cystectomy

Undergo radical cystectomy

BIOLOGICAL

Sacituzumab Govitecan

Given IV

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Washington

OTHER